Using anatomical T2-weighted MRI we have previously demonstrated the high chemosensitivity and acute regression of tumours arising in Th-MYCN mice to cyclophosphamide, used for frontline treatment of newly diagnosed neuroblastoma, and in response to other MYCN-targeted therapeutics [14,19]. The gene discussed is MYCN; the disease is neoplasm.